前列腺癌中泛素降解途径蛋白的表达及与临床病理特征的相关性

Correlations between Skp2,p27^(kipl),PTEN protein expression and the clinicopathological features of prostate cancer

目的探讨泛素降解途径蛋白Skp2、p27kipl和PTEN在前列腺癌中的表达及与前列腺癌各项临床病理特征的关系,并探讨三者的相关性。方法应用免疫组织化学法和图像分析系统研究41例前列腺癌标本、20例开放手术切除良性前列腺增生标本中Skp2、p27kipl和PTEN的表达情况。并使用Mann-Whitney检验、Spearman等级相关分析临床病理资料与免疫组化的结果及Skp2、p27kipl和PTEN之间的相关性。结果在前列腺癌中,Skp2蛋白染色阳性率显著高于良性前列腺增生(P<0.001),p27kipl蛋白染色阳性率显著低于良性前列腺增生(P<0.001),PTEN蛋白染色阳性率显著低于良性前列腺增生(P<0.001)。Skp2蛋白表达与前列腺癌术前PSA水平、肿瘤穿透前列腺被膜、肿瘤分期、病理分级密切相关(P<0.05)。而p27kipl和PTEN蛋白表达与上述临床病理特征负相关(P<0.05)。Spearman等级相关分析表明,Skp2与p27kipl蛋白表达呈负相关(r=-0.572,P<0.001),Skp2与PTEN蛋白表达呈负相关(r=-0.433,P=0.005)。结论Skp2蛋白在前列腺癌中表达增加,与术前PSA水平、局部浸润、临床分期和病理分级呈正相关,而p27蛋白在前列腺癌中表达降低,与上述临床病理特征呈负相关,Skp2蛋白表达与p27蛋白表达之间呈负相关。Skp2表达与抑癌基因PTEN蛋白表达呈负相关。

Objective To investigate the correlation between Skp2, p27^kipl, FFEN protein expression and the clinicopathological features of prostatic carcinoma, and the relationships between expression of Skp2, p27^kipl and FYEN in prostate cancer. Methods Skp2, p27^kipl and PTEN protein expression in the tissues of 41 human prostatic carcinomas as well as 20 benign prostatic hyperplasia（BPH） were studied using immunohistochemistry. Results The Skp2 labeling frequency in prostatic carcinoma were significantly higher than that in BPH （ P 〈 0. 001 ）. The p27^kipl labeling frequency in prostatic carcinoma was significantly lower than that in BPH （P 〈 0. 001 ）. The PTEN labeling frequency in prostatic carcinoma was also significantly lower than that in BPH （ P 〈 0. 001 ）. The Skp2 protein expression in prostatic carcinoma was positively correlated with preoperative serum prostate-specific antigen level, extraprostatic extension, clinical stage, and histological grade（ P 〈 0. 05）. The p27^kipl and PTEN protein expression in prostatic carcinoma were inversely correlated with preoperative serum prostate-specific antigen level, extraprostatic extension, clinical stage, and histological grade（P 〈 0. 05 ）. Conclusions Expression of Skp2 protein may lead to decrease in level of p27 in human prostatic carcinoma, indicating its involvement in the development of human prostatic carcinoma. In addition, Skp2 may be a new target for the treatment of prostate cancer.